ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms25010118 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Maria Teresa Bochicchio und 15 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori", 47014 Meldola, FC, Italy. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Hypereosinophilic Syndrome, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Italian Ministry of Health within the research line “Precision, gender and ethnicity-based medicine and geroscience: genetic-molecular mechanisms in the develo….
Abstract (Originalsprache)
ETV6::ABL1 rearranged neoplasms are rare hematological diseases. To date, about 80 cases have been reported, including myeloid and lymphoid leukemias. The ETV6 gene codes for an ETS family transcription factor and several fusion partners have been described. When translocated, ETV6 causes the constitutive activation of the partner genes. Here, we report the case of a 54-year-old woman with a cryptic insertion of the 3′ region of ABL1 in the ETV6 gene. The patient was first diagnosed with idiopathic hypereosinophilic syndrome, according to the clinical history, conventional cytogenetics, standard molecular analyses and pathologist description. Next generation sequencing of diagnosis samples unexpectedly detected both ETV6::ABL1 type A and B fusion transcripts, which were then confirmed by FISH. The diagnosis was Myeloid/Lymphoid neoplasm with ETV6::ABL1 fusion, and the patient received imatinib mesylate treatment. In a follow-up after more than one year, the patient still maintained the molecular and complete hematological responses. This case highlights the importance of timely and proper diagnostics and prompt tyrosine kinase inhibitor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori", 47014 Meldola, FC, Italy.
- Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori", 47014 Meldola, FC, Italy.
- Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, BO, Italy.
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40100 Bologna, BO, Italy.
- Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, BO, Italy.
- Fondazione Pisana per la Scienza ONLUS, 56017 San Giuliano Terme, PI, Italy.
ORCID-Profile: Maria Teresa Bochicchio, Giovanni Marconi, Carmen Baldazzi, Francesca Ruggieri, Alessandro Lucchesi, Elena Sabattini, Anna Ferrari, Giovanni Martinelli, Giorgia Simonetti
Förderung
- Italian Ministry of Health
- Italian Ministry of Health within the research line “Precision, gender and ethnicity-based medicine and geroscience: genetic-molecular mechanisms in the develo…
Zitieren
APA
Bochicchio, M. T., Marconi, G., Baldazzi, C., Bandini, L., Ruggieri, F., Lucchesi, A., Agostinelli, C., Sabattini, E., Orsatti, A., Ferrari, A., Capirossi, G., Servili, C., Ghelli Luserna di Rorà, A., Martinelli, G., Simonetti, G., & Rosti, G. (2023). ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25010118
Vancouver
Bochicchio MT, Marconi G, Baldazzi C, Bandini L, Ruggieri F, Lucchesi A, et al. ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms25010118
BibTeX
@article{Bochicchio2023,
author = {Bochicchio, Maria Teresa and Marconi, Giovanni and Baldazzi, Carmen and Bandini, Lorenza and Ruggieri, Francesca and Lucchesi, Alessandro and Agostinelli, Claudio and Sabattini, Elena and Orsatti, Agnese and Ferrari, Anna and Capirossi, Giorgia and Servili, Chiara and Ghelli Luserna di Rorà, Andrea and Martinelli, Giovanni and Simonetti, Giorgia and Rosti, Gianantonio},
title = {ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms25010118}
}
EUVIMED